Paradigm Shift in Metastatic TNBC to Trop2-Targeted Antibody-Drug Conjugates

(MedPage Today) — BERLIN — Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic triple-negative breast cancer (TNBC) ineligible for immunotherapy, according to two randomized trials…